These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28449419)

  • 1. Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta-analysis.
    Zhou X; Wu X; Sun H; Li J
    J Evid Based Med; 2017 May; 10(2):136-144. PubMed ID: 28449419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with tirofiban for acute coronary syndrome (ACS): a systematic review and network analysis.
    Lang SH; Manning N; Armstrong N; Misso K; Allen A; Di Nisio M; Kleijnen J
    Curr Med Res Opin; 2012 Mar; 28(3):351-70. PubMed ID: 22292469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention.
    Brown DL; Fann CS; Chang CJ
    Am J Cardiol; 2001 Mar; 87(5):537-41. PubMed ID: 11230835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: an Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy.
    Nazif TM; Mehran R; Lee EA; Fahy M; Parise H; Stone GW; Kirtane AJ
    Am Heart J; 2014 Jan; 167(1):43-50. PubMed ID: 24332141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
    Tricoci P; Newby LK; Hasselblad V; Kong DF; Giugliano RP; White HD; Théroux P; Stone GW; Moliterno DJ; Van de Werf F; Armstrong PW; Prabhakaran D; Rasoul S; Bolognese L; Durand E; Braunwald E; Califf RM; Harrington RA
    Circ Cardiovasc Qual Outcomes; 2011 Jul; 4(4):448-58. PubMed ID: 21712522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Intracoronary versus Intravenous Administration of Tirofiban during Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
    Tang X; Li R; Jing Q; Liu Y; Liu P
    PLoS One; 2015; 10(6):e0129718. PubMed ID: 26067296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
    Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of heparin, bivalirudin, and different glycoprotein IIb/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: A network meta-analysis.
    Lipinski MJ; Lee RC; Gaglia MA; Torguson R; Garcia-Garcia HM; Pichard AD; Satler LF; Waksman R
    Cardiovasc Revasc Med; 2016 Dec; 17(8):535-545. PubMed ID: 27842901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome.
    Friedland S; Eisenberg MJ; Shimony A
    Am J Cardiol; 2011 Nov; 108(9):1244-51. PubMed ID: 22000626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention.
    Schiariti M; Saladini A; Cuturello D; Missiroli B; Puddu PE
    J Cardiovasc Med (Hagerstown); 2011 Jan; 12(1):29-36. PubMed ID: 20639765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH; Harrington RA
    Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycoprotein IIb/IIIa inhibitors in patients with renal insufficiency undergoing percutaneous coronary intervention.
    Anderson JR; Riding D
    Cardiol Rev; 2008; 16(4):213-8. PubMed ID: 18562812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eptifibatide and tirofiban: new preparations. Limited benefit.
    Prescrire Int; 2000 Oct; 9(49):135-8. PubMed ID: 11603412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
    Cohen M
    Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: a meta-analysis of randomized trials.
    Sciahbasi A; Biondi-Zoccai G; Romagnoli E; Valgimigli M; Rasoul S; van't Hof A; Lioy E; Stone GW
    Int J Cardiol; 2012 Mar; 155(2):243-8. PubMed ID: 21035214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tirofiban and eptifibatide treatment of patients presenting with acute coronary syndrome with non-ST segment elevation.
    Corominas N; Perez J; Ortiz J; Ferrer E; Ribas J; Sanz G
    Pharm World Sci; 2004 Feb; 26(1):38-43. PubMed ID: 15018258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions.
    Liu T; Xie Y; Zhou YJ; Li YP; Ma HY; Guo YH; Liu YY; Zhao YX; Shi DM
    Chin Med J (Engl); 2009 Aug; 122(15):1732-7. PubMed ID: 19781316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
    Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.